Based on the earnings transcript, Amgen Inc. reported strong Q1 2019 results with mid-single digit volume growth and year-over-year non-GAAP EPS growth. The company's financial performance was driven by the growth of newer products like Prolia, Repatha, and Aimovig, as well as the launch of Evenity. The company also reported strong performance in its biosimilars business, with Kanjinti and Amgevita off to a strong start in Europe. Amgen's guidance for 2019 was raised, reflecting the company's confidence in its pipeline and potential for long-term growth. The company's strong balance sheet and cash flow position allowed it to continue to invest in its pipeline and provide significant returns to shareholders. Overall, the company's performance in Q1 2019 was strong, and the stock is likely to see positive impact in the short term.